**Table 1 :** Characteristics of patients treated by guided growth

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **N°** | **Age** | **Catonné** | **HKA** | | **MMPTA** | | **MDA** | | **MLFDA** | |
|  |  |  | **PO** | **LFU** | **PO** | **LFU** | **PO** | **LFU** | **PO** | **LFU** |
| 1 | 8 | 2 | 150 | 172 | 81 | 89 | 20 | 13 | 83 | 78 |
| 2 | 7 | 2 | 143 | 178 | 89 | 84 | 22 | 14 | 88 | 83 |
| 3 | 7 | 3 | 160 | 175 | 77 | 82 | 18 | 7 | 82 | 84 |
| 4 | 7 | 3 | 152 | 176 | 84 | 91 | 17 | 14 | 83 | 83 |
| 5 | 7 | 3 | 151 | 168 | 83 | 90 | 15 | 11 | 80 | 100 |
| 6 | 3,5 | 2 | 130 | 165 | 67 | 84 | 25 | 17 | 92 | 80 |
| 7 | 3,5 | 2 | 135 | 172 | 82 | 98 | 31 | 13 | 100 | 88 |
| 8 | 3 | 2 | 122 | 161 | 75 | 85 | 17 | 25 | 127 | 104 |
| 9 | 3 | 2 | 113 | 154 | 93 | 100 | 14 | 8 | 123 | 110 |
| 10 | 9 | 1 | 152 | 175 | 76 | 77 | 17 | 12 | 104 | 89 |
| 11 | 9 | 1 | 154 | 168 | 75 | 88 | 19 | 18 | 88 | 87 |
| 12 | 3 | 2 | 154 | 170 | 89 | 93 | 12 | 12 | 99 | 93 |
| 13 | 3 | 3 | 144 | 163 | 92 | 94 | 18 | 12 | 95 | 85 |
| 14 | 3 | 2 | 164 | 180 | 82 | 72 | 12 | 10 | 94 | 98 |
| **Médiane** |  |  | **150** | **171** | **82** | **88,5** | **17,5** | **12,5** | **93** | **87,5** |
| **P-value** |  |  | **0,001\*** | | **0,018\*** | | **0,013\*** | | **0,05** | |

**\***Significant result**; PO:** Pre-Operative; **LFU:** Latest Follow-Up

**Table II:** Characteristics of patients treated by revisited Rab osteotomy

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **N°** | **Age** | **Catonné** | **HKA** | | **MMPTA** | | **MDA** | | **MLFDA** | |
|  |  |  | **PO** | **LFU** | **PO** | **LFU** | **PO** | **LFU** | **PO** | **LFU** |
| 1\*\* | 4 | 3 | 142 | 150 | 90 | 99 | 14 | 10 | 112 | 115 |
| 2 | 5 | 3 | 160 | 175 | 81 | 92 | 13,5 | 7 | 106 | 105 |
| 3\*\* | 5 | 2 | 160 | 148 | 91 | 88 | 15 | 4 | 93 | 92 |
| 4\*\* | 12 | 3 | 163 | 162 | 85 | 92 | 16 | 15 | 103 | 101 |
| 5\*\* | 8 | 3 | 160 | 149 | 72 | 65 | 19 | 16 | 93 | 94 |
| 6\*\* | 8 | 3 | 163 | 165 | 83 | 76 | 17 | 8 | 96 | 89 |
| 7\*\* | 11 | 3 | 166 | 166 | 71 | 71 | 6 | 6 | 85 | 85 |
| 8 | 11 | 2 | 165 | 172 | 68 | 71 | 17 | 11 | 82 | 87 |
| 9 | 2,5 | 3 | 160 | 172 | 77 | 80 | 14 | 9 | 91 | 86 |
| 10 | 2,5 | 3 | 155 | 164 | 75 | 77 | 16 | 10 | 101 | 90 |
| **Médiane** |  |  | **160** | **165,5** | **79** | **78,5** | **15,5** | **9,5** | **94,5** | **91** |
| **P-value** |  |  | **0,31** | | **0,37** | | **0,01\*** | | **0,28** | |

**\***Significant result**;\*\*** Recurrence**; PO:** Pre-Operative; **LFU:** Latest Follow-Up